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Abstract
Cellular hypoxia is a fundamental mechanism of injury in the
critically ill. The study of human responses to hypoxia occurring as
a consequence of hypobaria defines the fields of high-altitude
medicine and physiology. A new paradigm suggests that the
physiological and pathophysiological responses to extreme
environmental challenges (for example, hypobaric hypoxia, hyper-
baria, microgravity, cold, heat) may be similar to responses seen in
critical illness. The present review explores the idea that human
responses to the hypoxia of high altitude may be used as a means
of exploring elements of the pathophysiology of critical illness.
Introduction
Hypoxaemia is a common consequence of critical illness.
Hypoxaemia in critical illness may be caused by hypo-
ventilation, ventilation/perfusion mismatch, right-to-left shunting
or limitation of diffusion across the alveolar–capillary membrane.
Hypoxaemia my also occur as a result of breathing a low
fractional inspired oxygen tension; for example, at high
altitude. Tissue hypoxia (reduced cellular or mitochondrial
oxygen availability) may arise as a consequence of hypoxaemia
or as a result of reduced oxygen delivery due to decreased
cardiac output or decreased red-cell concentration (anaemia).
Tissue hypoxia may also occur in association with the
systemic inflammatory response syndrome. This may be due
to decreased tissue oxygen delivery associated with
microcirculatory dysfunction, or may occur via alterations in
cellular energy pathways and mitochondrial function, resulting
in a decreased ability to utilise the available oxygen – a
phenomenon termed cellular dysoxia [1].
Conversely, tissue hypoxia may initiate and maintain many
aspects of critical illness. Hypoxic epithelial cell activation
releases tumour necrosis factor alpha and IL-8, resulting in
pathological increases in vascular permeability and in the
release of IL-6, the main cytokine of the acute-phase
response [2]. Hypoxia-mediated cell death will generate an
inflammatory response, further perpetuating the cascade of
critical illness. Furthermore, myocardial tissue hypoxia may
impair contractile function, thus reducing the total blood flow
and further exacerbating global tissue hypoxia [3].
Responses to continued hypoxaemia and tissue hypoxia may
prove detrimental in the long term. For example, in Monge’s
disease (chronic mountain sickness) occurring in natives or
long-life residents living above 2,500 metres, excessive
erythrocytosis coupled with hypoxic pulmonary vaso-
constriction may result in high pulmonary artery pressures
and cor pulmonale, leading to congestive heart failure [4,5].
Time may, however, also allow beneficial adaptive processes
that permit an individual to survive severe tissue hypoxia at
levels that, encountered more acutely, might prove fatal.
The mechanisms through which hypoxic adaptation occur are
poorly understood. Furthermore, exploring these mechanisms
in the context of critical illness is difficult. Critically ill patients
form a heterogeneous group; preadmission patient charac-
teristics (for example, age, fitness, comorbidities) and
precipitating illnesses (for example, trauma, infection,
ischaemic event) vary considerably. In addition, many
pathological and physiological processes occur concurrently,
and separating the cause and effect of just one feature of the
disease (tissue hypoxia) can prove extremely difficult. Hypoxic
adaptive processes are likely to be common to tissue hypoxia
whatever the cause, however, and studying healthy
individuals progressively exposed to hypoxia through ascent
to high altitude may inform of the nature of the hypoxic
adaptive processes occurring in critically ill patients. It might
be possible, in other words, to take knowledge ‘from
mountainside to bedside’. This approach offers the
advantages of a relatively homogeneous study population and
environmental challenge, in contrast to those observed on
critical care units, as well as the availability of ‘premorbid’
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information and levels of function. Finally, the approach also
offers an ethical alternative to hypoxia experimentation in
patients; all individuals involved are willing participants in
climbing or trekking ventures, as a consequence of which
they expose themselves to a hypoxic environment.
High-altitude physiology and pathophysiology
The troposphere is the lowest portion of the atmosphere and
envelopes the earth’s entire surface. Within the troposphere,
barometric pressure falls as altitude (vertical height above
sea level) increases. The concentration of oxygen in air
remains constant so, as the barometric pressure decreases,
the partial pressure of oxygen decreases proportionately. This
condition is referred to as hypobaric hypoxia. For reference,
the partial pressure of oxygen at the altitude of Everest Base
Camp (5,300 metres altitude) is about one-half of the sea-
level value. The summit of Mount Everest is the highest point
above sea level on the earth’s surface, at 8,850 metres
altitude, and has a partial pressure of oxygen about one-third
of the sea-level value.
High-altitude physiology may be divided into the study of
short-term changes that occur with exposure to hypobaric
hypoxia (the acute response to hypoxia) and studies of longer-
term acclimatisation and adaptation. Acute exposure to the
ambient atmosphere at extreme altitude (for example, above
8,000 metres) is rapidly fatal [6]. Acclimatisation is the set of
beneficial processes whereby lowland humans respond to a
reduced inspired partial pressure of oxygen. These changes
tend to reduce the gradient of oxygen partial pressure from
ambient air to tissues (classical oxygen cascade) and are
distinct from the pathological changes that lead to altitude
illness. Adaptation to high altitude describes changes that
have occurred over a number of generations as a result of
natural selection in a hypobaric hypoxic environment, and this
can be observed in some groups of high-altitude residents.
High-altitude illness may be divided into the acute syndromes
that affect lowland or highland residents ascending to
altitudes greater than those to which they are accustomed
and the chronic conditions that affect individuals resident at
high altitude for long periods. The acute adult syndromes of
high  altitude are acute mountain sickness, high-altitude
pulmonary oedema (HAPE) and high-altitude cerebral oedema.
Hypoxia and inflammation as mechanisms of
injury
Hypoxia fulfils criteria as a causative agent [7] for the acute
high-altitude illnesses. The incidence and severity of acute
mountain sickness, HAPE and high-altitude cerebral oedema
are related to the speed of ascent and the maximum height
gained, suggesting a dose–response type of relationship in
susceptible individuals [8]. A number of studies also suggest,
however, that inflammation may be contributory in the
pathogenesis of altitude illness [8-16]. Several studies have
failed to convincingly demonstrate any association between
an acute inflammatory response and the development of
acute mountain sickness [12,15,17]. On the other hand, a
number of studies have shown that individuals with pre-
existing inflammatory conditions (for example, diarrhoeal
illness, upper respiratory tract infection) have an increased
predisposition to acute high-altitude illnesses (that is, acute
high-altitude illnesses occur at lower altitudes or with slower
ascents) [8,13,14,18]. This pattern is consistent with Moore
and Moore’s ‘two hit model’ of critical illness initiation,
whereby a single insult primes the body for a much more
severe response to a secondary insult (for example, major
trauma followed by hypoxia and hypovolaemia) [19].
The initial pathogenesis in HAPE is thought to be nonuniform
hypoxic pulmonary vasoconstriction leading to pulmonary
capillary stress failure and a high-permeability type of oedema
in the face of a normal left atrial pressure [20]. Although
alveolar fluid in early HAPE does not demonstrate inflam-
matory activation [21], bronchoalveolar lavage fluid from
individuals with established HAPE has high levels of
inflammatory cells and mediators [9,10,16]. When broncho-
alveolar lavage was performed in the field, in patients
suffering from HAPE for 24 hours or less, there was a marked
increase in total cells, with macrophages being predominant,
along with elevated levels of cytokines including IL-6, IL-8 and
tumour necrosis factor alpha [10].
In hospitalised patients later in the course of HAPE, the
proportion of neutrophils increases and the observation is an
inflammatory process similar in magnitude and pattern to
acute respiratory distress syndrome in the critical care unit [9].
The development of an inflammatory component may modify
the natural history of HAPE; anecdotally, the recovery time for
HAPE (and high-altitude cerebral oedema) seems to be
related to the duration of illness. This might be explained by
postulating that in early HAPE, where mechanical capillary
stress failure leads to accumulation of intra-alveolar fluid, relief
of hypoxia will reduce pulmonary hypertension and the
oedema will rapidly resolve. In more established HAPE, where
significant inflammation has developed, resolution requires
reversal of the inflammatory state, and takes more time. A
similar pattern of injury may occur with critical illness: patients
who remain poorly resuscitated on the wards for prolonged
periods prior to their admission to critical care commonly have
a much more prolonged recovery duration than those who are
rapidly resuscitated following an initial insult. The study of the
interaction between hypoxia and inflammation as mechanisms
of injury occurring in healthy individuals in a hypoxic
environment has the potential to increase our understanding of
these interactions in the critically ill.
Physiological and metabolic responses to
hypoxia: increased delivery or decreased
utilisation
Parallels exist between the pattern of responses seen
following acute, in comparison with subacute, hypobaricPage 3 of 5
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hypoxia and those responses that occur during different
phases of critical illness.
The physiological response to acute hypobaric hypoxia
serves to increase oxygen delivery to the tissues: ventilation,
cardiac output and haemoglobin concentrations increase
(haemoglobin concentration increases initially by the haemo-
concentration and later as a result of increased erythro-
poiesis). Similarly, the textbook paradigm of acclimatisation to
hypobaric hypoxia emphasises the development of mechanisms
to increase oxygen flux (increase in ventilation, cardiac output,
oxygen carriage, and capillarity) [6].
These observations, however, do not adequately explain the
observed differences between individuals in their tolerance of
hypobaric hypoxic environments. Neither the baseline
cardiorespiratory performance (maximal oxygen consumption)
nor changes in the response to chronic hypoxia account for
differences between individuals in acclimatisation to
prolonged hypoxia [22] or performance at altitude [23].
Maximal oxygen consumption, maximal heart rate and stroke
volume are all reduced [24] after acclimatisation despite
normalisation of the blood oxygen content to sea-level values
(by an increase in haemoglobin concentration) [25]. Further-
more, pure oxygen breathing by acclimatised individuals
(which results in an oxygen content greater than that at sea
level) does not return maximal oxygen consumption to sea-
level values [26]. These surprising findings suggest that
oxygen carriage is not a limiting factor for maximal oxygen
consumption at altitude. This could be consistent with central
nervous system limitation of the maximal exercise capacity,
with limitation of oxygen flux within the tissues, or with a
downregulation of cellular metabolism.
An alternative model supported by empirical evidence
suggests that mechanisms not related to oxygen delivery may
play an even greater role: this alternative model proposes that
acclimatisation is achieved not solely by increasing the oxygen
flux, but also by decreasing utilisation. Acclimatisation may
therefore be mediated in part by alterations in oxygen delivery,
but also by reductions in cellular oxygen demand, perhaps
through hibernation/stunning or preconditioning pathways, or
through improvements in efficiency of use of metabolic
substrates. Indeed, hypoxia-tolerant systems rarely activate the
anaerobic metabolism but tend to favour a reduced energy
turnover state and reduce costly cellular activities such as ion-
pumping and protein turnover [27]. In this regard, it is
interesting to note that other hypoxia-tolerant species tend to
adapt to hypoxia by reducing demand (hibernation, reduced
metabolic rate) rather than increasing supply [27].
Might these mechanisms be paralleled in critical illness? The
available empirical data suggest that this might be so. Early in
critical illness (for example, severe sepsis, the immediate
perioperative setting or major trauma), when the mitochondrial
and metabolic activity is high [28], increasing oxygen delivery
(or maintaining normal oxygen delivery in the face of evidence
that the level is reduced) decreases subsequent mortality [29-
35]. Conversely, in established critical illness, increasing
oxygen delivery is at best of no benefit and may even increase
mortality [34-37]. In established critical illness, mitochondrial
activity and oxidative phosphorylation are reduced [28]; just as
such effects may be beneficial in acclimatisation to hypobaric
hypoxia, Singer and colleagues have proposed that such
‘reduced metabolic demand’ may offer protection against the
cellular hypoxia of critical illness [38].
In both critical illness and during exposure to hypoxia at
altitude the acute response seems to be to overcome tissue
hypoxia by compensating with increased oxygen delivery
(consistent with a fight or flight response) whereas the longer
term response seems focused on reducing utilisation,
perhaps through hibernation/stunning, through ‘precon-
ditioning’ phenomena [39] or through enhanced efficiency of
oxygen utilisation.
Exploring these differences by studying humans exposed to
the hypoxia of high altitude has the potential to identify
mechanisms important in established critical illness and
perhaps to alter our therapeutic focus towards increasing the
efficiency of oxygen utilisation rather than improving delivery.
Consistent with this model there is a suggestion that
improved performance at altitude associated with genotype II
of the angiotensin-converting enzyme (ACE) polymorphism
(see below) may be related to alterations in the efficiency of
oxygen utilisation [40].
Genes, hypoxia and adaptation
Just as in the outcome from critical illness, there is wide
variation between individuals regarding performance at high
altitude and susceptibility to high-altitude illness. This
phenotypic variation occurs as a result of genetic variation,
and the selection of ‘advantageous genetic variants’ may
underpin fundamental differences in the physiology of long-
term highland dwellers when compared with lowland
populations. Native Tibetan populations have been resident at
high altitude for hundreds of generations, whereas the Han
Chinese residents of Tibet have migrated from lowland
regions during the past 60 years. When compared with the
Han Chinese, native Tibetans have greater maximal oxygen
uptakes and vital capacities [41], a reduced alveolar–arterial
oxygen gradient [42], a higher arterial oxygen saturation at
birth and during the first 4 months of life [43], and an
increased uterine artery blood flow [44] leading to a
reduction in the incidence of intrauterine growth rate and of
low-birth-weight babies [45]. Some of these changes have
also been noted in South American Andean natives when
compared with lowland residents [46].
Among lowlanders ascending to high altitude, genetic
differences have been identified that confer performance
benefits at high altitude. Individuals homozygous for the
Available online http://ccforum.com/content/11/1/203insertion variant of the human ACE gene, which is associated
with reduced ACE levels, seem to perform better at altitude
[47,48]. The association of ACE polymorphisms with acute
and chronic high-altitude illnesses is more complex. In a
Japanese (lowland resident) population there was no
difference in the insertion/deletion allele distribution between
HAPE-resistant and HAPE-susceptible groups, although
pulmonary vascular resistance was higher in those individuals
with the D allele when they developed HAPE [49]. This
contrasts with studies in Kyrghyz (highland resident)
populations suggesting that high-altitude pulmonary
hypertension is associated with the ACE gene insertion (I)
allele [50,51]. There are also data suggesting that variants of
the endothelial nitric oxide synthase gene could be involved in
adaptation to altitude. Nitric oxide is synthesised in the lungs
and is involved in the regulation of pulmonary blood flow.
Exhaled nitric oxide levels are higher in native populations
resident at high altitude [52]. In Japanese subjects,
polymorphisms of the endothelial nitric oxide synthase gene
resulting in decreased nitric oxide synthesis were associated
with an increased susceptibility to HAPE [53]. In Caucasians,
however, no difference in nitric oxide synthase genotype
frequencies was found when comparing HAPE-susceptible
and HAPE-resistant individuals [54], and there was also no
association between pulmonary artery systolic pressure in
acute hypoxia and the nitric oxide synthase genotype [55].
The nitric oxide synthase gene polymorphisms associated
with lower nitric oxide activity were found to have an
increased frequency in Nepalese sherpas when compared
with nonsherpa lowland residents [56]. Interactions with
other gene systems will probably be responsible for the
contrasting effect of the ACE gene insertion allele and nitric
oxide synthase gene alleles observed in different groups.
If the paradigm proposed at the outset of the present review
has validity, then it would be expected that genes conferring
benefit for high-altitude performance might be related to
improved outcomes in critical illness. In keeping with this
hypothesis, the ACE gene insertion allele is associated not
only with improved performance at high altitude, but with a
lower mortality from acute respiratory distress syndrome
[57,58], improved outcomes in childhood meningococcal
septicaemia [59] and improved cardiorespiratory response to
premature birth [60].
Conclusion
Cellular hypoxia is a fundamental element of critical illness.
Studying human responses to hypobaric hypoxia may offer
important insights into the pathophysiology of critical illness.
Competing interests
The authors declare that they have no competing interests.
References
1. Brealey D, Brand M, Hargreaves I, Heales S, Land J, Smolenski R,
Davies NA, Cooper CE, Singer M: Association between mito-
chondrial dysfunction and severity and outcome of septic
shock. Lancet 2002, 360:219-223.
2. Bertges DJ, Fink MP, Delude RL: Hypoxic signal transduction in
critical illness. Crit Care Med 2000, 28(4 Suppl):N78-N86.
3. Allen DG, Orchard CH: Myocardial contractile function during
ischemia and hypoxia. Circ Res 1987, 60:153-168.
4. Ergueta J, Spielvogel H, Cudkowicz L: Cardio-respiratory
studies in chronic mountain sickness (Monge’s syndrome).
Respiration 1971, 28:485-517.
5. Leon-Velarde F, Maggiorini M, Reeves JT, Aldashev A, Asmus I,
Bernardi L, Ge RL, Hackett P, Kobayashi T, Moore LG, et al.:
Consensus statement on chronic and subacute high altitude
diseases. High Alt Med Biol 2005, 6:147-157.
6. Ward MP, Milledge JS, West JB: High Altitude Medicine and
Physiology. London: Arnold; 2000.
7. Hill AB: The environment and disease: association or causa-
tion? Proc R Soc Med 1965, 58:295-300.
8. Hackett PH, Roach RC: High-altitude illness. N Engl J Med
2001, 345:107-114.
9. Kubo K, Hanaoka M, Yamaguchi S, Hayano T, Hayasaka M,
Koizumi T, Fujimoto K, Kobayashi T, Honda T: Cytokines in bron-
choalveolar lavage fluid in patients with high altitude pul-
monary oedema at moderate altitude in Japan. Thorax 1996,
51:739-742.
10. Kubo K, Hanaoka M, Hayano T, Miyahara T, Hachiya T, Hayasaka
M, Koizumi T, Fujimoto K, Kobayashi T, Honda T: Inflammatory
cytokines in BAL fluid and pulmonary hemodynamics in high-
altitude pulmonary edema. Respir Physiol 1998, 111:301-310.
11. Kaminsky DA, Jones K, Schoene RB, Voelkel NF: Urinary
leukotriene E4 levels in high-altitude pulmonary edema. A
possible role for inflammation. Chest 1996, 110:939-945.
12. Bailey DM, Kleger GR, Holzgraefe M, Ballmer PE, Bartsch P:
Pathophysiological significance of peroxidative stress, neu-
ronal damage, and membrane permeability in acute mountain
sickness. J Appl Physiol 2004, 96:1459-1463.
13. Murdoch DR: Symptoms of infection and altitude illness
among hikers in the Mount Everest region of Nepal. Aviat
Space Environ Med 1995,66:148-151.
14. Durmowicz AG, Noordeweir E, Nicholas R, Reeves JT: Inflamma-
tory processes may predispose children to high-altitude pul-
monary edema. J Pediatr 1997, 130:838-840.
15. Klausen T, Olsen NV, Poulsen TD, Richalet JP, Pedersen BK:
Hypoxemia increases serum interleukin-6 in humans. Eur J
Appl Physiol Occup Physiol 1997, 76:480-482.
16. Schoene RB, Swenson ER, Pizzo CJ, Hackett PH, Roach RC,
Mills WJ Jr, Henderson WR Jr, Martin TR: The lung at high alti-
tude: bronchoalveolar lavage in acute mountain sickness and
pulmonary edema. J Appl Physiol 1988, 64:2605-2613.
17. Hartmann G, Tschop M, Fischer R, Bidlingmaier C, Riepl R,
Tschop K, Hautmann H, Endres S, Toepfer M: High altitude
increases circulating interleukin-6, interleukin-1 receptor
antagonist and C-reactive protein. Cytokine 2000, 12:246-252.
18. Bailey DM, Davies B, Castell LM, Collier DJ, Milledge JS, Hullin
DA, Seddon PS, Young IS: Symptoms of infection and acute
mountain sickness; associated metabolic sequelae and prob-
lems in differential diagnosis. High Alt Med Biol 2003, 4:319-
331.
19. Moore FA, Moore EE: Evolving concepts in the pathogenesis of
postinjury multiple organ failure. Surg Clin North Am 1995, 75:
257-277.
20. Bartsch P, Mairbaurl H, Maggiorini M, Swenson ER: Physiologi-
cal aspects of high-altitude pulmonary edema. J Appl Physiol
2005, 98:1101-1110.
21. Swenson ER, Maggiorini M, Mongovin S, Gibbs JS, Greve I, Mair-
baurl H, Bartsch P: Pathogenesis of high-altitude pulmonary
edema: inflammation is not an etiologic factor. JAMA 2002,
287:2228-2235.
22. Cymerman A, Reeves JT, Sutton JR, Rock PB, Groves BM, Mal-
conian MK, Young PM, Wagner PD, Houston CS: Operation
Everest II: maximal oxygen uptake at extreme altitude. J Appl
Physiol 1989, 66:2446-2453.
23. Howald H, Hoppeler H: Performing at extreme altitude: muscle
cellular and subcellular adaptations. Eur J Appl Physiol 2003,
90:360-364.
24. Sutton JR, Reeves JT, Groves BM, Wagner PD, Alexander JK, Hult-
gren HN, Cymerman A, Houston CS: Oxygen transport and car-
diovascular function at extreme altitude: lessons from Operation
Everest II. Int J Sports Med 1992, 13(Suppl 1):S13-S18.
Critical Care    Vol 11 No 1 Grocott et al.
Page 4 of 5
(page number not for citation purposes)25. Calbet JA, Boushel R, Radegran G, Sondergaard H, Wagner PD,
Saltin B: Why is VO2 max after altitude acclimatization still
reduced despite normalization of arterial O2 content? Am J
Physiol Regul Integr Comp Physiol 2003, 284:R304-R316.
26. Cerretelli P: Limiting factors to oxygen transport on Mount
Everest. J Appl Physiol 1976, 40:658-667.
27. Hochachka PW, Buck LT, Doll CJ, Land SC: Unifying theory of
hypoxia tolerance: molecular/metabolic defense and rescue
mechanisms for surviving oxygen lack. Proc Natl Acad Sci U S A
1996, 93:9493-9498.
28. Brealey D, Singer M: Mitochondrial dysfunction in sepsis. Curr
Infect Dis Rep 2003, 5:365-371.
29. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B,
Peterson E, Tomlanovich M: Early goal-directed therapy in the
treatment of severe sepsis and septic shock. N Engl J Med
2001, 345:1368-1377.
30. Shoemaker WC, Appel PL, Kram HB, Waxman K, Lee TS:
Prospective trial of supranormal values of survivors as thera-
peutic goals in high-risk surgical patients. Chest 1988,  94:
1176-1186.
31. Boyd O, Grounds RM, Bennett ED: A randomized clinical trial of
the effect of deliberate perioperative increase of oxygen
delivery on mortality in high-risk surgical patients. JAMA
1993, 270:2699-2707.
32. Wilson J, Woods I, Fawcett J, Whall R, Dibb W, Morris C,
McManus E: Reducing the risk of major elective surgery: ran-
domised controlled trial of preoperative optimisation of
oxygen delivery. BMJ 1999, 318:1099-1103.
33. Fleming A, Bishop M, Shoemaker W, Appel P, Sufficool W,
Kuvhenguwha A, Kennedy F, Wo CJ: Prospective trial of supra-
normal values as goals of resuscitation in severe trauma.
Arch Surg 1992, 127:1175-1179.
34. Kern JW, Shoemaker WC: Meta-analysis of hemodynamic opti-
mization in high-risk patients. Crit Care Med 2002, 30:1686-
1692.
35. Poeze M, Greve JW, Ramsay G: Meta-analysis of hemodynamic
optimization: relationship to methodological quality. Crit Care
2005, 9:R771-R779.
36. Hayes MA, Timmins AC, Yau EH, Palazzo M, Hinds CJ, Watson D:
Elevation of systemic oxygen delivery in the treatment of criti-
cally ill patients. N Engl J Med 1994, 330:1717-1722.
37. Gattinoni L, Brazzi L, Pelosi P, Latini R, Tognoni G, Pesenti A,
Fumagalli R: A trial of goal-oriented hemodynamic therapy in
critically ill patients. SvO2 Collaborative Group. N Engl J Med
1995, 333:1025-1032.
38. Singer M, De S V, Vitale D, Jeffcoate W: Multiorgan failure is an
adaptive, endocrine-mediated, metabolic response to over-
whelming systemic inflammation. Lancet 2004, 364:545-548.
39. Yellon DM, Downey JM: Preconditioning the myocardium: from
cellular physiology to clinical cardiology. Physiol Rev 2003, 83:
1113-1151.
40. Montgomery H, Clarkson P, Barnard M, Bell J, Brynes A, Dollery
C, Hajnal J, Hemingway H, Mercer D, Jarman P, et al.: Angio-
tensin-converting-enzyme gene insertion/deletion polymor-
phism and response to physical training. Lancet 1999, 353:
541-545.
41. Sun SF, Droma TS, Zhang JG, Tao JX, Huang SY, McCullough
RG, McCullough RE, Reeves CS, Reeves JT, Moore LG: Greater
maximal O2 uptakes and vital capacities in Tibetan than Han
residents of Lhasa. Respir Physiol 1990, 79:151-161.
42. Zhuang J, Droma T, Sutton JR, Groves BM, McCullough RE,
McCullough RG, Sun S, Moore LG: Smaller alveolar–arterial O2
gradients in Tibetan than Han residents of Lhasa (3658 m).
Respir Physiol 1996, 103:75-82.
43. Niermeyer S, Yang P, Shanmina, Drolkar, Zhuang J, Moore LG:
Arterial oxygen saturation in Tibetan and Han infants born in
Lhasa, Tibet. N Engl J Med 1995, 333:1248-1252.
44. Moore LG, Zamudio S, Zhuang J, Sun S, Droma T: Oxygen trans-
port in tibetan women during pregnancy at 3,658 m. Am J
Phys Anthropol 2001, 114:42-53.
45. Moore LG, Young D, McCullough RE, Droma T, Zamudio S:
Tibetan protection from intrauterine growth restriction (IUGR)
and reproductive loss at high altitude. Am J Hum Biol 2001,
13:635-644.
46. Haas JD, Baker PT, Hunt EE, Jr: The effects of high altitude on
body size and composition of the newborn infant in Southern
Peru. Hum Biol 1977, 49:611-628.
47. Montgomery HE, Marshall R, Hemingway H, Myerson S, Clarkson
P, Dollery C, Hayward M, Holliman DE, Jubb M, World M, et al.:
Human gene for physical performance. Nature 1998, 393:221-
222.
48. Tsianos G, Woolrich-Burt L, Aitchison T, Peacock A, Watt M,
Montgomery H, Watt I, Grant S: Factors affecting a climber’s
ability to ascend Mont Blanc. Eur J Appl Physiol 2006, 96:32-
36.
49. Hotta J, Hanaoka M, Droma Y, Katsuyama Y, Ota M, Kobayashi T:
Polymorphisms of renin–angiotensin system genes with high-
altitude pulmonary edema in Japanese subjects. Chest 2004,
126:825-830.
50. Morrell NW, Sarybaev AS, Alikhan A, Mirrakhimov MM, Aldashev
AA: ACE genotype and risk of high altitude pulmonary hyper-
tension in Kyrghyz highlanders. Lancet 1999, 353:814.
51. Aldashev AA, Sarybaev AS, Sydykov AS, Kalmyrzaev BB, Kim EV,
Mamanova LB, Maripov R, Kojonazarov BK, Mirrakhimov MM,
Wilkins MR, Morrell NW: Characterization of high-altitude pul-
monary hypertension in the Kyrgyz: association with
angiotensin-converting enzyme genotype. Am J Respir Crit
Care Med 2002, 166:1396-1402.
52. Beall CM, Laskowski D, Strohl KP, Soria R, Villena M, Vargas E,
Alarcon AM, Gonzales C, Erzurum SC: Pulmonary nitric oxide in
mountain dwellers. Nature 2001, 414:411-412.
53. Droma Y, Hanaoka M, Ota M, Katsuyama Y, Koizumi T, Fujimoto K,
Kobayashi T, Kubo K: Positive association of the endothelial
nitric oxide synthase gene polymorphisms with high-altitude
pulmonary edema. Circulation 2002, 106:826-830.
54. Weiss J, Haefeli WE, Gasse C, Hoffmann MM, Weyman J, Gibbs
S, Mansmann U, Bartsch P: Lack of evidence for association of
high altitude pulmonary edema and polymorphisms of the NO
pathway. High Alt Med Biol 2003, 4:355-366.
55. Smith EM, Baillie JK, Thompson AA, Irving JB, Porteous D, Webb
DJ: Endothelial nitric oxide synthase polymorphisms do not
influence pulmonary artery systolic pressure at altitude. High
Alt Med Biol 2006, 7:221-227.
56. Droma Y, Hanaoka M, Basnyat B, Arjyal A, Neupane P, Pandit A,
Sharma D, Miwa N, Ito M, Katsuyama Y, et al.: Genetic contribu-
tion of the endothelial nitric oxide synthase gene to high alti-
tude adaptation in sherpas. High Alt Med Biol 2006,
7:209–220.
57. Marshall RP, Webb S, Bellingan GJ, Montgomery HE, Chaudhari
B, McAnulty RJ, Humphries SE, Hill MR, Laurent GJ: Angiotensin
converting enzyme insertion/deletion polymorphism is asso-
ciated with susceptibility and outcome in acute respiratory
distress syndrome. Am J Respir Crit Care Med 2002, 166:646-
650.
58. Jerng JS, Yu CJ, Wang HC, Chen KY, Cheng SL, Yang PC: Poly-
morphism of the angiotensin-converting enzyme gene affects
the outcome of acute respiratory distress syndrome. Crit Care
Med 2006, 34:1001-1006.
59. Harding D, Baines PB, Brull D, Vassiliou V, Ellis I, Hart A,
Thomson AP, Humphries SE, Montgomery HE: Severity of
meningococcal disease in children and the angiotensin-con-
verting enzyme insertion/deletion polymorphism. Am J Respir
Crit Care Med 2002, 165:1103-1106.
60. Harding D, Dhamrait S, Marlow N, Whitelaw A, Gupta S,
Humphries S, Montgomery H: Angiotensin-converting enzyme
DD genotype is associated with worse perinatal cardiorespi-
ratory adaptation in preterm infants. J Pediatr 2003, 143:746-
749.
Available online http://ccforum.com/content/11/1/203
Page 5 of 5
(page number not for citation purposes)